GT Biopharma, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by GT Biopharma, Inc. (GTBP) on April 29, 2025. The company is incorporated in Delaware and its common stock trades on The Nasdaq Stock Market LLC. As of July 1, 2024, the company operates as a fully remote entity without a principal executive office.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes and does not contain financial statements or performance data.
Material Changes
The primary material change reported is the appointment of Michael Breen as Chief Executive Officer (CEO) for a two-year term, effective April 29, 2025. Mr. Breen had previously served as Interim CEO since March 2, 2022. He will continue to serve as a member of the Board of Directors and as Executive Chairman.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, management commentary on business performance, or discussion of risks and contingencies. The document details Mr. Breen's professional background, including his experience as a senior partner in global law firms specializing in corporate law, mergers and acquisitions, and fund management regulatory issues.
Key Facts for Investor Verification
- Michael Breen has been appointed CEO for a two-year term effective April 29, 2025.
- Mr. Breen retains his roles as Executive Chairman and Board Member.
- The company operates fully remotely with no physical principal executive office.
- No financial performance data or forward-looking guidance is included in this specific filing.